As a result of the coveted FDA listing as a medical device, UV Flu Technologies is confidently ramping up production towards servicing sales into the early adopter target market sector which includes high risk environments such as hospitals, medical practitioner's offices and institutions. Future sales efforts are anticipated to broaden the scope to include a wide variety of public facilities and consumer interests.

As of December 16, 2009, UV Flu Technologies, Inc. entered into an Asset Purchase Agreement with AmAirpure, Inc., whereby the Company acquires certain of their assets relating to the design, development, manufacture, sale and distribution of technology and products including air purification systems. The agreement includes the transfer of certain shares and contains customary representations and warranties and indemnification provisions.